The FTC Warned 24 Large Healthcare Companies That Following CMS Price Rules Is No Shield Against a Deception Case
A hospital can meet every CMS posting rule and still face an FTC deception case over the estimate a patient receives.
Topics
One Price in Japan, Response-Linked Payments in Australia and No Public Price in China: In Asia-Pacific the Payer Sets the CAR-T Price
One price in Japan, response-linked payments in Australia, no public price in China: CAR-T sponsors face three markets.
CMS Set December 2027 for Insurers’ Prescription Drug Price Files, a Requirement on Hold Since 2021
The drug file reaches manufacturers, and the schema due around May 2027 decides how much net price becomes public.
Only one Member State was assessing each valve when Brussels chose them, so the joint report will frame the evidence.
Only one Member State was assessing each valve when Brussels chose them, so the joint report will frame the evidence.
Korea’s First Homegrown GLP-1 Cut Weight 9.75% at 40 Weeks, So Hanmi Will Fight Wegovy and Mounjaro on Price and Supply
Hanmi’s GLP-1 trails Wegovy and Mounjaro on weight loss, so its case rests on a low starting price and Korean supply.
Denmark Said No to a DKK 2.5m CAR-T in January and Yes Once Kite Tied the Price to Response
Denmark turned a January no on Tecartus into a yes by tying price to response, and renewed burosumab on a lower price.
Out of 452 Brain Regions, an Overlooked Hypothalamic Nucleus Set the Volume on Stress in Mice
Out of 452 brain regions mapped in mice, an overlooked hypothalamic nucleus carried the memory of past stress.
Australia Set a Price Lilly Refused, So Lilly Built a Channel Around the PBS
Exclusion only works as leverage when the excluded drug has no market. Mounjaro has one, and Lilly built the channel.
Merck and Daiichi Pulled an ADC Filing as GSK Paid $110 Million for a KRAS Payload
Crowded topoisomerase I ADCs face a higher bar, while money moves to RAS payloads, bispecific ADCs and discovery tools.
ICER Says AstraZeneca’s $10,950 Baxfendy Is Worth $1,400 to $2,500 a Year
ICER has handed payers the case for putting Baxfendy behind generics, and Mineralys gets its price anchor before launch.